Viraspec is bringing to market a novel rapid diagnostic test for COVID-19 that is faster, less expensive, easier to use, more reliable, more accurate, and able to triage risk groups and those needing immunisation. Given the current COVID-19 pandemic, Viraspec will be focusing on bringing to market a test to meet this immediate need. Viraspec will initially target professional applications (hospitals and clinics (permanent and in-field) and home care), with the ambition to eventually target at-home applications.
Robert Porter has 28 years experience in the medical diagnostic arena. He has led product development for CE, FDA and cFDA registration, and founded and grown three successful business.
Did you know?
Current rapid COVID-19 tests are too slow, not cost-effective, burdensome to use, have sensitivity and accuracy issues.